OR WAIT null SECS
April 06, 2006
FTC Plans to Study Competitive Impacts of Authorized Generic Drugs
March 24, 2006
BMS, Sanofi-Aventis Settle Over Generic Plavix
March 09, 2006
GSK Loses Bid to Block Generic "Flonase"
November 23, 2005
GSK Study Questions Bioequivalency of Generic Cold Sore Creams
October 20, 2005
Roche Plans New US Manufacturing Facility for Tamiflu while Cipla Prepares to Market Generic
September 01, 2005
FDA Proposes Question-Based-Review System for Generics
New Guidance May Speed Generic Approvals
August 02, 2005
Being the first to gain the most is a fundamental principle in the generics business because several companies compete to create generics of successful products going off patent. For a generics company to maintain revenue growth in a market in which product prices continue to fall, it must secure a continuous flow of new products, with quality and speed to market being key drivers. Thus, generics companies must be highly skilled in product and process development (1), the generics business, and achieving bioequivalence-the most critical development area.
April 14, 2005
The Empire Strikes Back: Innovators Releasing Generic Drugs
April 02, 2005
Innovators and generics makers are staking out positions on follow-on proteins and other manufacturing issues.